Misplaced Pages

Congenital pseudarthrosis of the tibia (CPT) is a rare paediatric disease presenting with a bowing deformity of the tibia at birth or within the first decade of life. It is most commonly associated with Neurofibromatosis type 1 (NF-1). For children with CPT, pathological fracture of the tibia eventually occurs, resulting in persistent nonunion of the fracture site. If left untreated, leg deformities, joint stiffness, leg-length discrepancy and pain will persist. Diagnosis is done clinically and through X-ray imaging, with numerous classifications based on the severity of bowing and presence of fracture or intraosseous lesion.

Pathogenesis of CPT remains unclear. Genetic factors may be related due to its association with NF-1, but does not completely explain the development and location of CPT. It is likely related to the involvement of pathological periosteum in the tibia, resulting in abnormal bone turnover.

Treatment for CPT is through surgical correction, to limit the progression of deformity and to correct shortening of the affected limb. Prognosis of treatment depends on site and type of CPT, and there is a risk of recurrent fracture.

About 1 in 150,000 births present with CPT, but aside from its association with NF-1, not much else is shown from epidemiological studies.

Signs and symptoms

Primary CPT presents at birth or in infants as anterolateral bowing of the tibia. Bowing is observed as shortening of the corresponding leg, and is confirmed with X-ray imaging. It is commonly presented unilaterally, but can be bilateral.

Secondary CPT does not present with obvious bowing at birth and may be overlooked, but will eventually progress to pathological fracture as the infant grows. Approximately 50% of fractures occur before the patient is two years of age, when toddlers begin learning to walk.

CPT is characterized by persistent nonunion because of fractures of the tibia and the presence of fibrous tissue between parts of the fractured bone. The persistent nonunion eventually leads to the formation of a false joint, otherwise known as pseudarthrosis. This pseudarthrosis is a non-healing bone lesion, resulting in reduction of mobility and persistent pain in the lower leg.

Associated conditions

CPT is most commonly associated with NF-1, with around 50% of cases of CPT being developed from NF-1. A complete neurological and dermatological examination should be done for a newborn baby with anterolateral bowing of the tibia to screen for NF-1.

Diagnosis

Diagnosis is done through clinical examination and confirmed with radiographs of the tibia. Other associated clinical findings for NF-1, such as cafe-au-lait spots, neurofibromas and lisch nodules may also be found. “Early onset” CPT is regarded as fracture occurring <4 years old, while “late onset” CPT is regarded as fracture occurring >4 years old. Numerous other classifications have been proposed for CPT, owing to the heterogeneity of the disease. The Crawford and Boyd classifications are more traditional descriptive classifications emphasizing the presence of sclerosis, cystic and atrophic changes of the tibia. The Paley classification is a more recent classification which also takes into account the fibula for treatment and outcome.

Staging

Pathogenesis

The pathogenesis of CPT remains unclear nowadays. Various theories have been proposed in previous research, including mechanical, vascular, and genetic factors. However, none of these theories provide a comprehensive explanation for the development and location of CPT.

Extensive research has highlighted the significant role of fibrous hamartoma and pathological periosteum in the development of CPT. These factors are believed to hinder bone union by interposing mechanically and disrupt normal blood supply to the affected bone. The periosteum, in particular, may create a fibrous band that increases local pressure around the bone, leading to reduced vascularization and bone atrophy. Additionally, thickening of blood vessel walls in the pseudarthrosis area may contribute to the vascularization defect.

The association of NF-1 in a substantial portion (40 to 80%) of CPT cases suggests a potential genetic disorder. Neurofibromin 1 (NF1) is a gene that codes for a protein called neurofibromin, which plays a crucial role in regulating the Ras protein—a key player in cell differentiation and proliferation. Neurofibromin normally acts as a tumor suppressor by converting Ras-GTP to an inactive form (Ras-GDP). However, mutations in the NF1 gene result in the loss of neurofibromin function, leading to sustained activation of Ras. In certain CPT cases associated with NF-1, a double activation of the NF1 gene has been observed in the pseudarthrotic tissue. This genetic abnormality which only presents in some cases, cannot solely explain the pathogenesis of CPT. The loss of neurofibromin function can lead to disturbances in the Ras-MAPK pathway, resulting in impaired osteoblastic differentiation. Additionally, overexpression of the Ras pathway can increase the activity of osteoclasts and their precursors, contributing to bone resorption in CPT and the high incidence of recurrent fractures. In this case, the underlying pathogenic mechanisms of CPT likely involve a combination of signal abnormalities that enhance osteoclast activity, along with disturbances in osteoblastic differentiation, ultimately leading to defective bone remodeling. These processes are further exacerbated by the diminished local vascularization in the affected area.

Treatment

Ilizarov Fixation

Ilizarov fixation is an effective surgical approach for treating CPT, particularly when significant bone gaps or deformities are present. The technique involves applying an external fixator framework known as an Ilizarov apparatus. Composed of rings connected by wires and thin wires or half-pins inserted into the bone, the apparatus allows precise control over bone alignment by gradually distracting or compressing bone ends. Through application of regulated forces, the Ilizarov method stimulates new bone formation and facilitates bone union. Steady adjustments to the frame can progressively correct deformities, lengthen the bone, and induce consolidation across the pseudarthrosis site. This technique has been proven to have high healing rate and a low refracture rate later on in clinical practice.

Sofield Fragmentation

The Sofield fragmentation technique entails making numerous small bone fractures via controlled osteotomies (surgical bone cuts) in the affected region. Orthopaedic surgeons then stabilize and compress the resultant bone fragments securely using internal fixation devices like plates, screws or intramedullary rods. By intentionally fracturing the bone in a regulated manner and ensuring stability, Sofield fragmentation promotes healing while also assisting consolidation at the pseudarthrosis site.

Intramedullary Stabilization

Intramedullary stabilization involves inserting a rod or nail into the tibial medullary canal. This offers structural support from within the affected bone, allowing for bone alignment and union. Surgeons may opt for flexible or rigid intramedullary nails depending on patient-specific factors such as age, pseudarthrosis severity and any accompanying deformities. Although it almost guaranteed fracture healing and no refractures within a few years, the intramedullary nails would need to be replaced with age, leading to the pain of repeated surgery.

Free Vascularized Fibular Grafts

In cases of extensive tibial bone loss or compromised blood flow, surgeons may perform a free vascularized fibular graft. This involves harvesting a section of fibula (usually 10–12 cm long) along with its blood supply from the patient's leg and transplanting it to the pseudarthrosis site. As a vascularized graft, the fibula provides a fresh blood source to aid bone growth and repair at the defect location. This unconventional procedure is reserved for the most challenging clinical presentations, saving many children with CPT from amputation since it was invented in the 1990s. However, due to the lack of mechanical support, the healed bone has a high chance of refracture if this technique was applied alone for CPT treatment. Therefore, it is commonly applied together with intramedullary nails in recent years so as to deal with both tibial loss and low bone mechanical strength, and has demonstrated satisfying efficacy in clinical practice.

Prognosis

In general, 75% of CPT treatments result in initial union, with an average initial union time of 7.2 months. 35% of cases will result in refracture after treatment. Prognosis of treatment depends on several factors relating to the nature and history of the fracture. Age of diagnosis is one of the factors as fractures in older patients are associated with better prognosis. This could be due to the greater cross-sectional bone area, allowing for lower refracture rates. Early diagnosis and surgical treatment before the disease progresses is also associated with favourable results and minimized deformity. Site and type of pseudarthrosis have an impact on treatment success rate, as a lower location of fracture increases the complexity of the surgical operation due to the proximity with the ankle joint. More severe types of pseudarthrosis, such as those with severe bone deformities and significant leg length shortening is also associated with poor prognosis. Patients with a history of multiple surgical interventions and recurrent fractures also indicate poor prognosis, and suggest a high risk of refracture after treatment.

Epidemiology

CPT is a rare disease in children, with an estimated frequency of 1 in 150,000 births. Few epidemiological studies for CPT have been done, so the racial and gender distribution is unknown. From its association with NF-1, it is found that around 50 percent of cases of CPT develop from NF-1, though recent studies found the percentage may be as high as 84%, due to CPT being diagnosed before other more subtle signs of NF-1 appear. In NF-1 cases, CPT occurs in infancy in approximately 5 percent of persons, with a male predominance of 1.7:1.

References

1. ^ Pannier S (November 2011). "Congenital pseudarthrosis of the tibia". Orthopaedics & Traumatology, Surgery & Research. 97 (7): 750–761. doi:10.1016/j.otsr.2011.09.001. PMID 21996526.
2. ^ Van Royen K, Brems H, Legius E, Lammens J, Laumen A (September 2016). "Prevalence of neurofibromatosis type 1 in congenital pseudarthrosis of the tibia". European Journal of Pediatrics. 175 (9): 1193–1198. doi:10.1007/s00431-016-2757-z. PMID 27519821.
3. ^ Agrawal U, Tiwari V (2024). "Congenital Tibial Pseudarthrosis". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 35015468. Retrieved 2024-04-10.
4. ^ Hefti F, Bollini G, Dungl P, Fixsen J, Grill F, Ippolito E, et al. (January 2000). "Congenital pseudarthrosis of the tibia: history, etiology, classification, and epidemiologic data". Journal of Pediatric Orthopedics. Part B. 9 (1): 11–15. doi:10.1097/01202412-200001000-00003. PMID 10647103.
5. "Congenital Pseudarthrosis of the Tibia (CPT) | Pediatric Orthopaedic Society of North America (POSNA)". posna.org. Retrieved 2024-04-10.
6. ^ Kesireddy N, Kheireldin RK, Lu A, Cooper J, Liu J, Ebraheim NA (November 2018). "Current treatment of congenital pseudarthrosis of the tibia: a systematic review and meta-analysis". Journal of Pediatric Orthopedics. Part B. 27 (6): 541–550. doi:10.1097/BPB.0000000000000524. PMID 29878977.
7. ^ Paley D (April 2019). "Congenital pseudarthrosis of the tibia: biological and biomechanical considerations to achieve union and prevent refracture". Journal of Children's Orthopaedics. 13 (2): 120–133. doi:10.1302/1863-2548.13.180147. PMC 6442511. PMID 30996736.
8. ^ Galois L, Girard D, Diligent J, Gasnier J, Bensoussan D, Mainard D (October 2004). "199 Résultats de la greffe de moelle osseuse dans les pseudarthroses et retards de consolidation de jambe : à propos de 20 observations". Revue de Chirurgie Orthopédique et Réparatrice de l'Appareil Moteur. 90 (6): 121. doi:10.1016/s0035-1040(04)70650-9. ISSN 0035-1040.
9. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. (February 2007). "Guidelines for the diagnosis and management of individuals with neurofibromatosis 1". Journal of Medical Genetics. 44 (2): 81–88. doi:10.1136/jmg.2006.045906. PMC 2598063. PMID 17105749.
10. Ly KI, Blakeley JO (November 2019). "The Diagnosis and Management of Neurofibromatosis Type 1". The Medical Clinics of North America. 103 (6): 1035–1054. doi:10.1016/j.mcna.2019.07.004. PMID 31582003.
11. "Disorders of the Leg", Tachdjian's Pediatric Orthopaedics, Elsevier, pp. 973–1033, 2008, doi:10.1016/b978-1-4160-2221-3.50026-8, ISBN 978-1-4160-2221-3
12. Laufer A, Frommer A, Gosheger G, Roedl R, Schiedel F, Broeking JN, et al. (December 2020). "Reconstructive Approaches in Surgical Management of Congenital Pseudarthrosis of the Tibia". Journal of Clinical Medicine. 9 (12): 4132. doi:10.3390/jcm9124132. PMC 7767548. PMID 33371504.
13. Crawford AH, Bagamery N (January 1986). "Osseous manifestations of neurofibromatosis in childhood". Journal of Pediatric Orthopedics. 6 (1): 72–88. doi:10.1097/01241398-198601000-00015. PMID 3079778.
14. Boyd HB (June 1982). "Pathology and Natural History of Congenital Pseudarthrosis of the Tibia". Clinical Orthopaedics and Related Research. 166: 5–13. doi:10.1097/00003086-198206000-00003. ISSN 0009-921X.
15. Xie JH, Mei HB, Liu K, Zhu GH, Ouyang YQ, Huang Y, et al. (July 2022). "Analysis of related factors of behavioral problems in children with congenital pseudarthrosis of tibia". Revista da Associacao Medica Brasileira. 68 (7): 893–897. doi:10.1590/1806-9282.20211197. PMC 9574966. PMID 35946764.
16. Ari B, Kuyubasi SN (May 2021). "Bilateral congenital pseudarthrosis of the tibia with neurofibromatosis type 1". JPMA. The Journal of the Pakistan Medical Association. 71 (5): 1499–1502. doi:10.47391/jpma.504. PMID 34091645.
17. Lee DY, Cho TJ, Lee HR, Lee K, Moon HJ, Park MS, et al. (September 2011). "Disturbed osteoblastic differentiation of fibrous hamartoma cell from congenital pseudarthrosis of the tibia associated with neurofibromatosis type I". Clinics in Orthopedic Surgery. 3 (3): 230–237. doi:10.4055/cios.2011.3.3.230. PMC 3162204. PMID 21909471.
18. "Review for "New insights of periosteum proteomics analysis on pathogenesis of congenital pseudarthrosis of tibia in children"". Rapid Communications in Mass Spectrometry. 2022-08-01. doi:10.1002/rcm.9374/v2/review1.
19. ^ Crawford AH, Schorry EK (May 2006). "Neurofibromatosis update". Journal of Pediatric Orthopedics. 26 (3): 413–423. doi:10.1097/01.bpo.0000217719.10728.39. PMID 16670560.
20. Chung E (December 2012). "Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)". Pediatric Imaging Cases. Oxford University Press. pp. 275–276. doi:10.1093/med/9780199758968.003.0131. ISBN 978-0-19-975896-8.
21. Sakamoto A, Yoshida T, Yamamoto H, Oda Y, Tsuneyoshi M, Iwamoto Y (July 2007). "Congenital pseudarthrosis of the tibia: analysis of the histology and the NF1 gene". Journal of Orthopaedic Science. 12 (4): 361–365. doi:10.1007/s00776-007-1142-1. PMID 17657556.
22. Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, et al. (February 2009). "Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression". Bone. 44 (2): 243–250. doi:10.1016/j.bone.2008.10.050. PMID 19061981.
23. Cho TJ, Seo JB, Lee HR, Yoo WJ, Chung CY, Choi IH (December 2008). "Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1". The Journal of Bone and Joint Surgery. American Volume. 90 (12): 2735–2744. doi:10.2106/jbjs.h.00014. hdl:10371/67451. PMID 19047720.
24. ^ Banchhor H, Chimurkar V (December 2022). "Congenital Pseudoarthrosis of the Tibia: A Narrative Review". Cureus. 14 (12): e32501. doi:10.7759/cureus.32501. PMC 9840411. PMID 36654595.
25. ^ Zhu GH, Mei HB, He RG, Liu YX, Liu K, Tang J, et al. (October 2016). "Combination of intramedullary rod, wrapping bone grafting and Ilizarov's fixator for the treatment of Crawford type IV congenital pseudarthrosis of the tibia: mid-term follow up of 56 cases". BMC Musculoskeletal Disorders. 17 (1): 443. doi:10.1186/s12891-016-1295-1. PMC 5075394. PMID 27770774.
26. Yalikun A, Yushan M, Hamiti Y, Lu C, Yusufu A (2022). "Combination of the Ilizarov Method and Intramedullary Fixation for the Treatment of Congenital Pseudarthrosis of the Tibia in Children: A Retrospective Observational Study". Frontiers in Surgery. 9: 901262. doi:10.3389/fsurg.2022.901262. PMC 9152179. PMID 35656087.
27. Sofield HA, Millar EA (December 1959). "Fragmentation, Realignment, and Intramedullary Rod Fixation of Deformities of the Long Bones in Children". The Journal of Bone & Joint Surgery. 41 (8): 1371–1391. doi:10.2106/00004623-195941080-00001. ISSN 0021-9355.
28. Charnley J (April 1956). "Congenital Pseudarthrosis of the Tibia Treated by the Intramedullary Nail". The Journal of Bone & Joint Surgery. 38 (2): 283–290. doi:10.2106/00004623-195638020-00004. ISSN 0021-9355.
29. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker PL (June 2004). "Use of an intramedullary rod for treatment of congenital pseudarthrosis of the tibia. A long-term follow-up study". The Journal of Bone and Joint Surgery. American Volume. 86 (6): 1186–1197. doi:10.2106/00004623-200406000-00010. PMID 15173291.
30. Shaw P (2012-07-30). "Recommendation of NIH Image to ImageJ: 25 years of image analysis". Faculty Opinions. doi:10.3410/f.717968566.793456800.
31. Liu Y, Yang G, Zhu G, Tan Q, Wu J, Liu K, et al. (August 2021). "Application of the "telescopic rod" in a combined surgical technique for the treatment of congenital pseudarthrosis of the tibia in children". Journal of Orthopaedic Surgery and Research. 16 (1): 532. doi:10.1186/s13018-021-02649-2. PMC 8390273. PMID 34446041.
32. Weiland AJ, Weiss AP, Moore JR, Tolo VT (June 1990). "Vascularized fibular grafts in the treatment of congenital pseudarthrosis of the tibia". The Journal of Bone and Joint Surgery. American Volume. 72 (5): 654–662. doi:10.2106/00004623-199072050-00003. PMID 2355026.
33. Dormans JP, Krajbich JI, Zuker R, Demuynk M (September–October 1990). "Congenital pseudarthrosis of the tibia: treatment with free vascularized fibular grafts". Journal of Pediatric Orthopedics. 10 (5): 623–628. doi:10.1097/01241398-199009000-00010. PMID 2394816.
34. Hagan KF, Buncke HJ (June 1982). "Treatment of Congenital Pseudarthrosis of the Tibia with Free Vascularized Bone Graft". Clinical Orthopaedics and Related Research. 166: 34. doi:10.1097/00003086-198206000-00007. ISSN 0009-921X.
35. Minami A, Ogino T, Sakuma T, Usui M (January 1987). "Free vascularized fibular grafts in the treatment of congenital pseudarthrosis of the tibia". Microsurgery. 8 (3): 111–116. doi:10.1002/micr.1920080302. PMID 3670033.
36. Beris AE, Lykissas MG, Kostas-Agnantis I, Vasilakakos T, Vekris MD, Korompilias AV (March 2010). "Congenital pseudarthrosis of the radius treated with gradual distraction and free vascularized fibular graft: case report". The Journal of Hand Surgery. 35 (3): 406–411. doi:10.1016/j.jhsa.2009.11.022. PMID 20133088.
37. El-Gammal TA, El-Sayed A, Kotb MM, Saleh WR, Ragheb YF, Refai OA, et al. (March 2021). "Crawford Type IV Congenital Pseudarthrosis of the Tibia: Treatment With Vascularized Fibular Grafting and Outcome at Skeletal Maturity". Journal of Pediatric Orthopedics. 41 (3): 164–170. doi:10.1097/BPO.0000000000001751. PMID 33448723.
38. El-Gammal TA, Ali AE, Kotb MM, Saleh WR, Ragheb YF, Refai OA, et al. (July 2023). "Congenital Pseudarthrosis of the Tibia: Long-term Outcome of Treatment With Intramedullary Vascularized Fibular Graft Combined With Ilizarov Distraction". Journal of Pediatric Orthopedics. 43 (6): e487–e492. doi:10.1097/BPO.0000000000002399. PMID 36941117.
39. Zargarbashi R, Bagherpour A, Keshavarz-Fathi M, Panjavi B, Bagherpour Zarchi M (August 2021). "Prognosis of Congenital Pseudarthrosis of the Tibia: Effect of Site of Tibial Pseudarthrososis and Fibular Involvement". Journal of Pediatric Orthopedics. 41 (7): 422–427. doi:10.1097/BPO.0000000000001861. PMID 34001806.
40. Ohnishi I, Sato W, Matsuyama J, Yajima H, Haga N, Kamegaya M, et al. (March 2005). "Treatment of congenital pseudarthrosis of the tibia: a multicenter study in Japan". Journal of Pediatric Orthopedics. 25 (2): 219–224. doi:10.1097/01.bpo.0000151054.54732.0b. PMID 15718906.
41. Stevenson DA, Birch PH, Friedman JM, Viskochil DH, Balestrazzi P, Boni S, et al. (June 1999). "Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1". American Journal of Medical Genetics. 84 (5): 413–419. doi:10.1002/(sici)1096-8628(19990611)84:5<413::aid-ajmg5>3.0.co;2-1. PMID 10360395.

• Congenital disorders of musculoskeletal system
• Tibia